TY - JOUR
T1 - Adapting COVID-19 research infrastructure to capture influenza and respiratory syncytial virus alongside SARS-CoV-2 in UK healthcare workers winter 2022/23
T2 - Results of a pilot study in the SIREN cohort
AU - SIREN Study Group
AU - Foulkes, Sarah
AU - Munro, Katie
AU - Sparkes, Dominic
AU - Broad, Jonathan
AU - Platt, Naomi
AU - Howells, Anna
AU - Akinbami, Omolola
AU - Khawam, Jameel
AU - Joshi, Palak
AU - Russell, Sophie
AU - Norman, Chris
AU - Price, Lesley
AU - Corrigan, Diane
AU - Cole, Michelle
AU - Timeyin, Jean
AU - Forster, Louise
AU - Slater, Katrina
AU - Watson, Conall H.
AU - Andrews, Nick
AU - Charlett, Andre
AU - Atti, Ana
AU - Islam, Jasmin
AU - Brown, Colin S.
AU - Turner, Jonathan
AU - Hopkins, Susan
AU - Hall, Victoria
AU - Northfield, John
AU - Cutler, Sean
AU - Roynon, Anna
AU - Thompson, Catherine
AU - Emmett, Hannah
AU - Conneely, Joanna
AU - Hettiarachchi, Nipunadi
AU - Adaji, Enemona
AU - Chand, Meera
AU - O’Connell, Anne Marie
AU - Brooks, Tim
AU - Zambon, Maria
AU - Ramsay, Mary
AU - Saei, Ayoub
AU - Linley, Ezra
AU - Tonge, Simon
AU - Otter, Ashley
AU - D'Arcangelo, Silvia
AU - Rowe, Cathy
AU - Semper, Amanda
AU - Gallagher, Eileen
AU - Howell, Kate
AU - Hewson, Jacqueline
AU - Sajedi, Noshin
N1 - Publisher Copyright:
© 2025 Foulkes et al.
PY - 2025/5
Y1 - 2025/5
N2 - Introduction The combination of patient illness and staff absence driven by seasonal viruses culminates in annual “winter pressures” on UK healthcare systems and has been exacerbated by COVID-19. In winter 2022/23 we introduce multiplex testing aiming to determine the incidence of SARS-CoV-2, influenza and respiratory syncytial virus (RSV) in our cohort of UK healthcare workers (HCWs). Methods The pilot study was conducted from 28/11/2022–31/03/2023 within the SIREN prospective cohort study. Participants completed fortnightly questionnaires, capturing symptoms and sick leave, and multiplex PCR testing for SARS-CoV-2, influenza and RSV, regardless of symptoms. PCR-positivity rates by virus were calculated over time, and viruses were compared by symptoms and severity. Self-reported symptoms and associated sick leave were described. Sick leave rates were compared by vaccination status and demographics. Results 5,863 participants were included, 84.6% female, 70.3%≥45-years, 91.4% of White ethnicity and 82.6% in a patient facing role. PCR-positivity peaked in early December for all three viruses (4.6 positives per 100 tests (95%CI 3.5, 5.7) SARS-CoV-2, 3.9 (95%CI 2.2, 5.6) influenza, 1.4 (95%CI 0.4, 2.4) RSV), declining to <0.3/100 tests after January for influenza/RSV, and around 2.5/100 tests for SARS-CoV-2. Over one-third of all infections were asymptomatic, and symptoms were similar for all viruses. 1,368 (23.3%) participants reported taking sick leave, median 4 days (range 1–59). Rates of sick leave were higher in participants with co-morbidities, working in clinical settings, and who had not been vaccinated (COVID-19 booster or seasonal influenza vaccine) versus those who had received neither vaccine (2.04 vs 1.41 sick days/100 days, adjusted Incidence Rate Ratio 1.47 (95%CI 1.38, 1.56). Conclusion This pilot demonstrated the use of multiplex testing allowed better understanding of the impact of seasonal respiratory viruses and respective vaccines on the HCW workforce. This highlights the important information on asymptomatic infection and persisting levels of SARS-CoV-2 infection.
AB - Introduction The combination of patient illness and staff absence driven by seasonal viruses culminates in annual “winter pressures” on UK healthcare systems and has been exacerbated by COVID-19. In winter 2022/23 we introduce multiplex testing aiming to determine the incidence of SARS-CoV-2, influenza and respiratory syncytial virus (RSV) in our cohort of UK healthcare workers (HCWs). Methods The pilot study was conducted from 28/11/2022–31/03/2023 within the SIREN prospective cohort study. Participants completed fortnightly questionnaires, capturing symptoms and sick leave, and multiplex PCR testing for SARS-CoV-2, influenza and RSV, regardless of symptoms. PCR-positivity rates by virus were calculated over time, and viruses were compared by symptoms and severity. Self-reported symptoms and associated sick leave were described. Sick leave rates were compared by vaccination status and demographics. Results 5,863 participants were included, 84.6% female, 70.3%≥45-years, 91.4% of White ethnicity and 82.6% in a patient facing role. PCR-positivity peaked in early December for all three viruses (4.6 positives per 100 tests (95%CI 3.5, 5.7) SARS-CoV-2, 3.9 (95%CI 2.2, 5.6) influenza, 1.4 (95%CI 0.4, 2.4) RSV), declining to <0.3/100 tests after January for influenza/RSV, and around 2.5/100 tests for SARS-CoV-2. Over one-third of all infections were asymptomatic, and symptoms were similar for all viruses. 1,368 (23.3%) participants reported taking sick leave, median 4 days (range 1–59). Rates of sick leave were higher in participants with co-morbidities, working in clinical settings, and who had not been vaccinated (COVID-19 booster or seasonal influenza vaccine) versus those who had received neither vaccine (2.04 vs 1.41 sick days/100 days, adjusted Incidence Rate Ratio 1.47 (95%CI 1.38, 1.56). Conclusion This pilot demonstrated the use of multiplex testing allowed better understanding of the impact of seasonal respiratory viruses and respective vaccines on the HCW workforce. This highlights the important information on asymptomatic infection and persisting levels of SARS-CoV-2 infection.
UR - http://www.scopus.com/inward/record.url?scp=105006481455&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0316131
DO - 10.1371/journal.pone.0316131
M3 - Article
C2 - 40402987
AN - SCOPUS:105006481455
SN - 1932-6203
VL - 20
JO - PLoS ONE
JF - PLoS ONE
IS - 5 May
M1 - e0316131
ER -